Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension

European Journal of Ophthalmology

Volumn 23, Issue 1, 2013, Pages 47-54

  Baudouin, Christophe ^a,b,c   Renard, Jean Paul ^d   Nordmann, Jean Philippe ^a   Denis, Philippe ^e   Lachkar, Yves ^f   Sellem, Eric ^g   Rouland, Jean François ^h   Jeanbat, Viviane ⁱ   Bouée, Stéphane ⁱ  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d University of Paris Descartes   (France)

^e CROIX ROUSSE HOSPITAL   (France)

^f SAINT JOSEPH HOSPITAL   (France)

^g Centre Ophtalmologique Kleber   (France)

^h UNIV LILLE   (France)

ⁱ CEMKA EVAL   (France)

Author keywords

Benzalkonium chloride; Dry eye; Glaucoma; Ocular surface disease; Preservatives

Indexed keywords

ANTIGLAUCOMA AGENT; EYE DROPS;

ADULT; AGED; ARTICLE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG TOLERABILITY; DRY EYE; EPIPHORA; EYE BURNING; EYE DISEASE; EYELID DISEASE; FEMALE; FOREIGN BODY; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; RISK FACTOR; SYMPTOMATOLOGY;

EID: 84877871072     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000181     Document Type: Article

References (28)

1. Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010; 29: 312-34.
2. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86: 418-23.
3. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17: 341-9.
4. Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1593-601.
5. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008; 17: 350-5.
6. Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressurelowering medications. Cornea 2010; 29: 618-21.
7. Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol 2010; 88: 329-36.
8. Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology 1989; 96: 327-35.
9. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication.I.The conjunctival cell profile. Arch Ophthalmol 1994; 112: 1437-45.
10. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication.II.The outcome of filtration surgery. Arch Ophthalmol 1994; 112: 1446-54.
11. Nuzzi R, Vercelli A, Finazzo C, Cracco C. Conjunctiva and subconjunctival tissue in primary open-angle glaucoma after long-term topical treatment: an immunohistochemical and ultrastructural study. Graefes Arch Clin Exp Ophthalmol 1995; 233: 154-62.
12. Baudouin C, Brignole F, Becquet F, Pisella PJ, Goguel A.Flow cytometry in impression cytology specimens. A new method for evaluation of conjunctival inflammation. Invest Ophthalmol Vis Sci 1997; 38: 1458-64.
13. Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology 1994; 101: 454-60.
14. Baudouin C, Hamard P, Liang H, Creuzot-Garcher C, Bensoussan L, Brignole F. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 2004; 111: 2186-92.
15. Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology 2008; 115: 109-15.
16. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004; 45: 1360-8.
17. Nordmann JP, Auzanneau N, Ricard S, Berdeaux G. Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes 2003; 1: 75.
18. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-13, discussion 829-30.
19. Dry Eye WorkShop. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5: 93-107.
20. Rossi GC, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol 2009; 19: 572-9.
21. Zimmerman TJ, Hahn SR, Gelb L, Tan H, Kim EE. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther 2009; 25: 145-52.
22. Herreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 1992; 99: 1082-8.
23. Lavin MJ, Wormald RP, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol 1990; 108: 1543-8.
24. Rolando M, Brezzo V, Giordano G, et al. The effect of different benzalkonium chloride concentrations on human normal ocular surface. In: Van Bijsterveld O, Lemp M, Spinelli D, eds. The Lacrimal System. Amsterdam: Kugler and Ghedini Publications; 1991.
25. Ichijima H, Petroll WM, Jester JV, Cavanagh HD. Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride. Cornea 1992; 11: 221-5.
26. Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther 2008; 25: 743-51.
27. Martone G, Frezzotti P, Tosi GM, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol 2009; 147: 725-35.
28. Pauly A, Meloni M, Brignole-Baudouin F, Warnet JM, Baudouin C. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest Ophthalmol Vis Sci 2009; 50: 1644-52.